The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- Living with Sarcoidosis: A Family Story of Strength and Awareness
- FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives
- FSR Research Report: FSR at the American Academy of Dermatology
- Ten Years with Sarcoidosis — Still Riding, Still Breathing
- A Kaleidoscope Inspires FSR’s “See Sarcoidosis” Awareness Month Campaign